Peking Union Medical College Hospital: Lymphoma, T-Cell, Peripheral trials

The registry lists 11 Lymphoma, T-Cell, Peripheral studies with Peking Union Medical College Hospital as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 8Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaRecruitingNCT06824883Phase 2
• Golidocitinib Plus CHOP in Newly Diagnosed PTCLRecruitingNCT06739265Phase 1/2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center StudyRecruitingNCT06083701Phase 1/2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyRecruitingNCT06037239Phase 1/2
• Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCLRecruitingNCT05441761Phase 1/2
• Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell LymphomaRecruitingNCT05075460Phase 3
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
• Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
• Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
• The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
• Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2